AEs by maximum grade in the LTE period
AEs, n (%) . | All-Cause AEs (n = 16)∗ . | Treatment-related AEs (n = 16) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All grades . | Grade 1 . | Grade 2 . | Grade 3† . | Grade 4 . | All grades . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | |
| Patient with ≥1 AE | 13 (81) | 12 (75) | 7 (44) | 2 (13) | 2 (13) | 3 (19) | 2 (13) | 2 (13) | 0 | 0 |
| Upper respiratory tract infection | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
| Rhinorrhea | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
| Vulvovaginal dryness | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
| Cough | 1 (6) | 1 (6) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
| Diarrhea | 2 (13) | 2 (13) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
| Back pain | 3 (19) | 3 (19) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arthralgia | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rash | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COVID-19 | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pneumonia | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Thrombocytosis | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Migraine | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulmonary embolism | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypertension | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| COVID-19 pneumonia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
AEs, n (%) . | All-Cause AEs (n = 16)∗ . | Treatment-related AEs (n = 16) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All grades . | Grade 1 . | Grade 2 . | Grade 3† . | Grade 4 . | All grades . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | |
| Patient with ≥1 AE | 13 (81) | 12 (75) | 7 (44) | 2 (13) | 2 (13) | 3 (19) | 2 (13) | 2 (13) | 0 | 0 |
| Upper respiratory tract infection | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
| Rhinorrhea | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
| Vulvovaginal dryness | 1 (6) | 0 | 1 (6) | 0 | 0 | 1 (6) | 0 | 1 (6) | 0 | 0 |
| Cough | 1 (6) | 1 (6) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
| Diarrhea | 2 (13) | 2 (13) | 0 | 0 | 0 | 1 (6) | 1 (6) | 0 | 0 | 0 |
| Back pain | 3 (19) | 3 (19) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arthralgia | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rash | 2 (13) | 1 (6) | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COVID-19 | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pneumonia | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Thrombocytosis | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Migraine | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Pulmonary embolism | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypertension | 1 (6) | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 | 0 |
| COVID-19 pneumonia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 1 (6) | 0 | 0 | 0 | 1 (6) | 0 | 0 | 0 | 0 | 0 |
Includes treatment-related AEs occurring in ≥1 patient and all-cause AEs for ≥2 patients or any that were grade 3 or 4.
Grade 3 AEs due to any cause occurred in 2 patients including 1 case each of COVID-19, thrombocytosis, migraine, and pulmonary embolism in 1 patient and hypertension in a second patient.